Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:INTINASDAQ:LTRNNASDAQ:SCYXNYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINTIInhibitor Therapeutics$0.04$0.05$0.03▼$0.10$7.49M-0.5314,323 shsN/ALTRNLantern Pharma$3.21+4.6%$3.44$2.55▼$6.12$33.11M1.5562,296 shs27,512 shsSCYXSCYNEXIS$0.74+1.5%$0.88$0.72▼$2.29$28.49M1.65160,633 shs198,746 shsVNRXVolitionRx$0.77-10.3%$0.54$0.40▼$0.94$88.61M1.07205,496 shs323,420 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINTIInhibitor Therapeutics0.00%-10.60%-26.32%-38.00%-45.06%LTRNLantern Pharma-3.46%-4.06%-6.69%-20.26%-26.02%SCYXSCYNEXIS-0.57%-7.01%-5.93%-29.13%-62.56%VNRXVolitionRx-6.51%+20.28%+66.85%+55.56%+32.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINTIInhibitor Therapeutics0.4076 of 5 stars0.05.00.00.01.00.00.0LTRNLantern Pharma1.6056 of 5 stars3.52.00.00.00.60.80.6SCYXSCYNEXIS0.1796 of 5 stars0.02.00.00.00.60.80.6VNRXVolitionRx1.5852 of 5 stars3.50.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINTIInhibitor Therapeutics 0.00N/AN/AN/ALTRNLantern Pharma 3.00Buy$25.00678.82% UpsideSCYXSCYNEXIS 0.00N/AN/AN/AVNRXVolitionRx 3.00Buy$3.50353.49% UpsideCurrent Analyst Ratings BreakdownLatest INTI, VNRX, SCYX, and LTRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025VNRXVolitionRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/30/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/8/2025VNRXVolitionRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$2.50 ➝ $2.504/2/2025LTRNLantern PharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/31/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINTIInhibitor TherapeuticsN/AN/AN/AN/A$0.01 per shareN/ALTRNLantern PharmaN/AN/AN/AN/A$1.96 per shareN/ASCYXSCYNEXIS$3.75M7.71N/AN/A$1.45 per share0.51VNRXVolitionRx$1.31M60.77N/AN/A($0.11) per share-7.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINTIInhibitor Therapeutics-$3.34M-$0.01N/A∞N/AN/A-120.86%-55.21%8/4/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.84N/AN/AN/AN/A-83.26%-70.65%8/6/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.56N/A14.82N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.27N/A∞N/A-2,321.14%N/A-163.39%N/ALatest INTI, VNRX, SCYX, and LTRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025LTRNLantern Pharma-$0.49-$0.42+$0.07-$0.42N/AN/A5/15/2025Q1 2025SCYXSCYNEXIS-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million3/28/2025Q4 2024INTIInhibitor TherapeuticsN/A-$0.01N/A-$0.01N/AN/A3/27/2025Q4 2024LTRNLantern Pharma-$0.51-$0.54-$0.03-$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINTIInhibitor TherapeuticsN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINTIInhibitor TherapeuticsN/A46.6846.68LTRNLantern PharmaN/A4.864.86SCYXSCYNEXISN/A5.835.83VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINTIInhibitor TherapeuticsN/ALTRNLantern Pharma28.62%SCYXSCYNEXIS54.37%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipINTIInhibitor Therapeutics4.60%LTRNLantern Pharma7.31%SCYXSCYNEXIS4.86%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINTIInhibitor Therapeutics1172.57 million164.64 millionNot OptionableLTRNLantern Pharma2010.78 million10.00 millionOptionableSCYXSCYNEXIS6039.02 million37.12 millionOptionableVNRXVolitionRx80103.02 million80.80 millionOptionableINTI, VNRX, SCYX, and LTRN HeadlinesRecent News About These CompaniesVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 12, 2025 | msn.comVolitionRx (NYSE:VNRX) Coverage Initiated at Jones TradingJune 10, 2025 | marketbeat.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of StockJune 5, 2025 | insidertrades.comVolition Announces Two Oral Presentations at Asian Meeting of Animal Medicine SpecialtiesJune 4, 2025 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Director Buys $10,800.00 in StockJune 4, 2025 | marketbeat.comVolitionRX shares hold as Benchmark maintains ratingMay 21, 2025 | uk.investing.comVolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of StockMay 20, 2025 | insidertrades.comVolitionRx Limited Announces Successful Detection of Nucleosomes in CatsMay 19, 2025 | prnewswire.comVolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advancesMay 16, 2025 | msn.comVolitionRX Limited (VNRX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comVolitionRx Limited Announces First Quarter 2025 Financial Results and Business UpdateMay 15, 2025 | prnewswire.comVolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business UpdateMay 12, 2025 | prnewswire.comVolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoptionMay 7, 2025 | prnewswire.comVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29, 2025 | prnewswire.comVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comVolitionRx initiated with a Buy at H.C. WainwrightApril 8, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationApril 8, 2025 | msn.comEarnings call transcript: VolitionRx revenue beats forecast in Q4 2024April 2, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhy Dollar General May Be Retail’s Most Undervalued ReboundBy Jeffrey Neal Johnson | June 2, 2025View Why Dollar General May Be Retail’s Most Undervalued ReboundINTI, VNRX, SCYX, and LTRN Company DescriptionsInhibitor Therapeutics OTCMKTS:INTI$0.04 0.00 (0.00%) As of 06/23/2025Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.Lantern Pharma NASDAQ:LTRN$3.21 +0.14 (+4.56%) Closing price 04:00 PM EasternExtended Trading$3.18 -0.02 (-0.78%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.SCYNEXIS NASDAQ:SCYX$0.74 +0.01 (+1.52%) Closing price 04:00 PM EasternExtended Trading$0.75 +0.01 (+1.34%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.VolitionRx NYSE:VNRX$0.77 -0.09 (-10.27%) Closing price 03:59 PM EasternExtended Trading$0.75 -0.02 (-2.69%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
